Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Autologous Matrix-induced Chondrogenesis Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Autologous Matrix-induced Chondrogenesis Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Hyaluronic Acid
      • 1.3.3 Collagen
      • 1.3.4 Polyethylene Glycol (PEG)
      • 1.3.5 Poly Lactic-Co-Glycolic Acid (PGLA)
    • 1.4 Market Segment by Application
      • 1.4.1 Global Autologous Matrix-induced Chondrogenesis Market Share by Application (2019-2025)
      • 1.4.2 Knees Joint
      • 1.4.3 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Autologous Matrix-induced Chondrogenesis Market Size
      • 2.1.1 Global Autologous Matrix-induced Chondrogenesis Revenue 2014-2025
      • 2.1.2 Global Autologous Matrix-induced Chondrogenesis Sales 2014-2025
    • 2.2 Autologous Matrix-induced Chondrogenesis Growth Rate by Regions
      • 2.2.1 Global Autologous Matrix-induced Chondrogenesis Sales by Regions 2014-2019
      • 2.2.2 Global Autologous Matrix-induced Chondrogenesis Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Autologous Matrix-induced Chondrogenesis Sales by Manufacturers
      • 3.1.1 Autologous Matrix-induced Chondrogenesis Sales by Manufacturers 2014-2019
      • 3.1.2 Autologous Matrix-induced Chondrogenesis Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Autologous Matrix-induced Chondrogenesis Revenue by Manufacturers (2014-2019)
      • 3.2.2 Autologous Matrix-induced Chondrogenesis Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Autologous Matrix-induced Chondrogenesis Market Concentration Ratio (CR5 and HHI)
    • 3.3 Autologous Matrix-induced Chondrogenesis Price by Manufacturers
    • 3.4 Key Manufacturers Autologous Matrix-induced Chondrogenesis Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Autologous Matrix-induced Chondrogenesis Market
    • 3.6 Key Manufacturers Autologous Matrix-induced Chondrogenesis Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Hyaluronic Acid Sales and Revenue (2014-2019)
      • 4.1.2 Collagen Sales and Revenue (2014-2019)
      • 4.1.3 Polyethylene Glycol (PEG) Sales and Revenue (2014-2019)
      • 4.1.4 Poly Lactic-Co-Glycolic Acid (PGLA) Sales and Revenue (2014-2019)
    • 4.2 Global Autologous Matrix-induced Chondrogenesis Sales Market Share by Type
    • 4.3 Global Autologous Matrix-induced Chondrogenesis Revenue Market Share by Type
    • 4.4 Autologous Matrix-induced Chondrogenesis Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Autologous Matrix-induced Chondrogenesis Sales by Application

    6 United States

    • 6.1 United States Autologous Matrix-induced Chondrogenesis Breakdown Data by Company
    • 6.2 United States Autologous Matrix-induced Chondrogenesis Breakdown Data by Type
    • 6.3 United States Autologous Matrix-induced Chondrogenesis Breakdown Data by Application

    7 European Union

    • 7.1 European Union Autologous Matrix-induced Chondrogenesis Breakdown Data by Company
    • 7.2 European Union Autologous Matrix-induced Chondrogenesis Breakdown Data by Type
    • 7.3 European Union Autologous Matrix-induced Chondrogenesis Breakdown Data by Application

    8 China

    • 8.1 China Autologous Matrix-induced Chondrogenesis Breakdown Data by Company
    • 8.2 China Autologous Matrix-induced Chondrogenesis Breakdown Data by Type
    • 8.3 China Autologous Matrix-induced Chondrogenesis Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Autologous Matrix-induced Chondrogenesis Breakdown Data by Company
    • 9.2 Rest of World Autologous Matrix-induced Chondrogenesis Breakdown Data by Type
    • 9.3 Rest of World Autologous Matrix-induced Chondrogenesis Breakdown Data by Application
    • 9.4 Rest of World Autologous Matrix-induced Chondrogenesis Breakdown Data by Countries
      • 9.4.1 Rest of World Autologous Matrix-induced Chondrogenesis Sales by Countries
      • 9.4.2 Rest of World Autologous Matrix-induced Chondrogenesis Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 JRI Orthopaedics Ltd
      • 10.1.1 JRI Orthopaedics Ltd Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.1.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.1.5 JRI Orthopaedics Ltd Recent Development
    • 10.2 BioTissue
      • 10.2.1 BioTissue Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.2.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.2.5 BioTissue Recent Development
    • 10.3 Anika Therapeutics
      • 10.3.1 Anika Therapeutics Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.3.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.3.5 Anika Therapeutics Recent Development
    • 10.4 B. Braun Melsungen
      • 10.4.1 B. Braun Melsungen Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.4.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.4.5 B. Braun Melsungen Recent Development
    • 10.5 Arthro-Kinetics
      • 10.5.1 Arthro-Kinetics Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.5.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.5.5 Arthro-Kinetics Recent Development
    • 10.6 Geistlich Pharma
      • 10.6.1 Geistlich Pharma Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.6.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.6.5 Geistlich Pharma Recent Development
    • 10.7 CartiHeal
      • 10.7.1 CartiHeal Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.7.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.7.5 CartiHeal Recent Development
    • 10.8 Matricel
      • 10.8.1 Matricel Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.8.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.8.5 Matricel Recent Development
    • 10.9 Smith & Nephew
      • 10.9.1 Smith & Nephew Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.9.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.9.5 Smith & Nephew Recent Development
    • 10.10 Zimmer Biomet Holdings
      • 10.10.1 Zimmer Biomet Holdings Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Autologous Matrix-induced Chondrogenesis
      • 10.10.4 Autologous Matrix-induced Chondrogenesis Product Introduction
      • 10.10.5 Zimmer Biomet Holdings Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Autologous Matrix-induced Chondrogenesis Sales Channels
      • 11.2.2 Autologous Matrix-induced Chondrogenesis Distributors
    • 11.3 Autologous Matrix-induced Chondrogenesis Customers

    12 Market Forecast

    • 12.1 Global Autologous Matrix-induced Chondrogenesis Sales and Revenue Forecast 2019-2025
    • 12.2 Global Autologous Matrix-induced Chondrogenesis Sales Forecast by Type
    • 12.3 Global Autologous Matrix-induced Chondrogenesis Sales Forecast by Application
    • 12.4 Autologous Matrix-induced Chondrogenesis Forecast by Regions
      • 12.4.1 Global Autologous Matrix-induced Chondrogenesis Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Autologous Matrix-induced Chondrogenesis Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      utologous matrix-induced chondrogenesis (AMIC) is a 1-step cartilage restoration technique that combines microfracture with the use of an exogenous scaffold.
      The functional principle of microfracturing is based on the release of multipotent mesenchymal progenitor cells, cytokines and growth factors from the subchondral bone. 
      In 2019, the market size of Autologous Matrix-induced Chondrogenesis is 100 million US$ and it will reach 180 million US$ in 2025, growing at a CAGR of 7.6% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Autologous Matrix-induced Chondrogenesis.

      This report studies the global market size of Autologous Matrix-induced Chondrogenesis, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Autologous Matrix-induced Chondrogenesis sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      JRI Orthopaedics Ltd
      BioTissue
      Anika Therapeutics
      B. Braun Melsungen
      Arthro-Kinetics
      Geistlich Pharma
      CartiHeal
      Matricel
      Smith & Nephew
      Zimmer Biomet Holdings

      Market Segment by Product Type
      Hyaluronic Acid
      Collagen
      Polyethylene Glycol (PEG)
      Poly Lactic-Co-Glycolic Acid (PGLA)

      Market Segment by Application
      Knees Joint
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Autologous Matrix-induced Chondrogenesis status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Autologous Matrix-induced Chondrogenesis manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Autologous Matrix-induced Chondrogenesis are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now